2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Checkpoint Inhibitor, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, MPN, CML, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Animal Model
PAPER

5497 MPN endothelial colony-forming cells (CFU-ECs) have increased tissue factor expression and decreased KLF2

Jihyun Song, PhD, Valentina Marchetti, PhD2, Soo Jin Kim, MS3, Changwhan Moon4, Swapan Dasgupta, PhD5, Perumal Thiagarajan, MD6, Josef Prchal, MD7
1 Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
2 STEMCELL Technologies, Vancouver, British Columbia, Canada
3 Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
4 Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
5 Baylor College of Medicine, Houston, Texas, United States
6 Baylor College of Medicine, Houston, Texas, United States
7 Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States

Thrombosis is a major cause of morbidity and mortality in myeloproliferative neoplasms (MPNs). JAK2V617F mutation is a principal driver mutation of clonal hematopoiesis in MPNs, it has also been detected colony-forming unit-endothelial cells (CFU-ECs), while the rare circulating endothelial progenitors that can repopulate endothelium are JAK2V617F negative (PMID: 17053059). Here, we examined potential role of CFU-ECs in contributing to thromboses.

Tissue factor (TF), encoded by the F3 gene, initiates the extrinsic coagulation pathway and contributes to the prothrombotic state in MPNs. Although monocytes are traditionally considered a major circulating cellular source of TF, our previous studies demonstrated that granulocytes from patients with JAK2V617F-positive MPNs have greater F3 expression and have increased TF activity than monocytes (PMID: 34748652). Because endothelial cells also contribute to thrombosis, we investigated whether the CFU-ECs represent an additional source of tissue factor in MPNs.

We studied 16 patients with JAK2V617F-mutated essential thrombocythemia (ET), 12 with polycythemia vera (PV), 5 with myelofibrosis (MF), 6 with germline JAK2 variants (K33T, E846D, R989fs, and R715T), 8 with increased HIF activity due to VHL, EGLN1, or EPAS1 mutations, and 8 healthy controls. CFU-ECs were expanded from peripheral blood mononuclear cells using the EC-Cult™ XF kit (STEMCELL Technologies). Transcript levels of F3, the antithrombotic transcription factor KLF2, and HIF-regulated genes (LDHA, SLC2A1, and VEGFA) were measured in CFU-ECs and paired granulocytes. JAK2V617F was assessed in DNA from CFU-ECs and compared with next-generation sequencing (NGS) results from matched peripheral blood clinical samples.

Compared with healthy controls, F3 expression was increased approximately 30-fold in CFU-ECs and 32-fold in granulocytes in patients with MPNs (P=0.0003 and P<0.0001, respectively). F3 expression was higher in patients with a history of thrombosis than in those without thrombosis, although the difference in this study did not reach statistical significance in either CFU-ECs or granulocytes. Among 30 patients with paired F3 expression measurements, 18 had higher expression in CFU-ECs than in granulocytes, with CFU-EC-to-granulocyte fold differences ranging from 1.65 to 43.94. In this study, JAK2V617F was also detected in CFU-ECs, but the paucity of available DNA precluded quantification of variant allele frequency. KLF2 is an antithrombotic transcription factor and an important negative regulator of F3 expression that is downregulated in both PV and ET granulocytes and platelets. However, KLF2 expression is further reduced in patients with a history of thrombosis in platelets but not in granulocytes (PMID: 36343116). In this study, KLF2 expression was also reduced in CFU-ECs from patients with PV and ET compared to controls` CFU-ECs (42 %, p=0.0320). F3 has been identified as a HIF-responsive gene (PMID: 41191539). The HIF-responsive genes LDHA, SLC2A1, and VEGFA were upregulated in both CFU-ECs and granulocytes from patients with PV and ET. In CFU-ECs, F3 expression correlated positively with LDHA (Spearman r=0.794, P<0.0001), SLC2A1 (r=0.626, P<0.0001), and VEGFA (r=0.518, P=0.0006), suggesting that HIF signaling may contribute to tissue factor regulation in these cells. However, increased F3 expression was not observed in patients with germline JAK2 mutations (K33T, E846D, R989fs, R715T) nor HIF-pathway mutations (VHL, EGLN1 and EPAS1) causing erythrocytosis, suggesting that the marked upregulation of F3 in MPNs cannot be explained by JAK2 or HIF activation alone and may require additional disease-specific factors in MPNs.

We report that the peripheral blood-derived CFU-ECs from MPN patients have markedly increased F3 expression, which was higher relative to their matched granulocytes. The strong positive correlations between F3 and HIF-responsive genes suggest that HIF-pathway activation may contribute to tissue factor regulation in CFU-ECs, cells also derived from the MPN clone. These findings identify CFU-ECs as an additional source of procoagulant activity in MPNs. Ongoing studies will determine whether increased F3 expression corresponds to enhanced tissue factor activity and evaluate its relationships with JAK2V617F variant allele frequency, treatment exposure, and clinical thrombotic events.

 

Jihyun Song, PhD: No relevant conflicts of interest to declare.